Banner

Short-term results of custom ablation stable over 2 years

Article

Higher-order aberrations decreased in most patients, with the change from baseline reaching up to 50%.

Related Videos
Related Content

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

September 28th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

September 27th 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

September 28th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

September 27th 2023

Kriya announces exclusive license, collaboration, agreement with Everads to advance gene therapies for diseases in ophthalmology, Including GA

September 28th 2023

EyePod: Transforming the MIGS pipeline into clinical reality

September 26th 2023

David Huang, MD, PhD, receives Lasker Award for transformative imaging technology

September 28th 2023

EyePod: Week in Review - September 17, 2023

September 23rd 2023

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US

September 27th 2023
© 2023 MJH Life Sciences

All rights reserved.